WellPet™ Fluralaner Efficacy and Pharmacokinetics in Dogs, 45-Day Study

Two complementary studies evaluated a novel fluralaner tablet formulation in dogs. The pharmacokinetic study measured plasma concentrations in 12 dogs up to 49 days post-treatment, reporting a peak concentration of 3,763 μg/L and an elimination half-life of 17.88 days. The efficacy study, involving 12 dogs split into treated and control groups, demonstrated sustained flea and tick control above regulatory thresholds for 45 days.

Use Cases

• Model pharmacokinetic profiles based on reported Cmax, Tmax, AUC, and half-life values
• Evaluate sustained efficacy of parasiticide treatments based on reported flea and tick efficacy percentages over 45 days
• Compare treatment regimens using the reported 45-day retreatment interval data

Strengths

• Pharmacokinetic parameters (Cmax, Tmax, AUC, t½) are reported with specific numerical values
• Efficacy results are reported with precise percentages for tick and flea control over multiple evaluation days
• Study design details are provided, including sample sizes (12 dogs per study) and infestation protocols

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (12.8 KB), suggesting limited scope

Provenance

Source

Breno Cayeiro Cruz

Collection Method

Data likely originates from two controlled clinical studies (pharmacokinetic and efficacy) conducted on dogs.

Freshness

Last updated 2026-04-10 07:01:53; freshness should be verified